Oxycodone

DEA Class; Rx

Common Brand Names; OxyContin, Xtampza ER, Roxicodone, Oxaydo, RoxyBond

Phenanthrene opioid agonist
Used for moderate to severe pain
Some products formulated to deter abuse by inhalation or injection

Known or suspected GI obstruction, including paralytic ileus

Hypersensitivity (eg, anaphylaxis) to oxycodone

Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment

Use caution in patients with anemia, cardiac arrhythmias, drug abuse or dependence, emotional lability, gallbladder disease, gout, head injury, renal/hepatic disease or impairment, hypoprothrombinemia, toxic psychosis, hypothyroidism, increased intracranial pressure, prostatic hypertrophy, renal impairment, seizures with epilepsy, thyrotoxicosis, urethral stricture, urinary tract surgery, vitamin K deficiency, anoxia, central nervous system (CNS) depression, hypercapmia, respiratory depression or disease, hypersensitivity to phenantrene-derivative opioid agonists, morbid obesity, untreated myxedema, adrenocrotical insufficiency including Addison disease

If crushed, extended-release preparation (OxyContin) can deliver large opiate dose with potential for abuse or overdose; OxyContin reformulated in April 2010 to prevent tablet from being cut, broken, crushed, or dissolved to release more medication; inability to tamper with product reduces potential for abuse

Caution with OxyContin in patients who have difficulty swallowing or have underlying GI disorders that may predispose to obstruction

May obscure diagnosis of acute abdominal conditions

Avoid use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic; mixed agonist/antagonist and partial agonist analgesics may reduce analgesic effect and/or precipitate withdrawal symptoms; when discontinuing therapy in physically-dependent patient, gradually taper dosage; do not abruptly discontinue therapy in these patients

Prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome

Drug is present in breast milk; published lactation studies report variable concentrations of drug in breast milk with administration of immediate-release formulation to nursing mothers in early postpartum period